197 related articles for article (PubMed ID: 18971577)
1. Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy.
Costanzo A; Talamonti M; Spallone G; Botti E; Chimenti MS; Papoutsaki M; Chimenti S
Dermatology; 2009; 218(2):146-50. PubMed ID: 18971577
[TBL] [Abstract][Full Text] [Related]
2. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
Papp KA; Bressinck R; Fretzin S; Goffe B; Kempers S; Gordon KB; Caro I; Walicke PA; Wang X; Menter A;
Int J Dermatol; 2006 May; 45(5):605-14. PubMed ID: 16700803
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment of plaque psoriasis with efalizumab: an Italian experience.
Costanzo A; Peris K; Talamonti M; Di Cesare A; Fargnoli MC; Botti E; Chimenti S
Br J Dermatol; 2007 Apr; 156 Suppl 2():17-23. PubMed ID: 17371319
[TBL] [Abstract][Full Text] [Related]
4. The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital.
Antoniou C; Stefanaki I; Stratigos A; Avgerinou G; Stavropoulos P; Potouridou I; Polidorou D; Moustou AE; Kosmadaki M; Katsambas AD
Br J Dermatol; 2007 Apr; 156 Suppl 2():12-6. PubMed ID: 17371318
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
[TBL] [Abstract][Full Text] [Related]
6. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
Lebwohl M; Tyring SK; Hamilton TK; Toth D; Glazer S; Tawfik NH; Walicke P; Dummer W; Wang X; Garovoy MR; Pariser D;
N Engl J Med; 2003 Nov; 349(21):2004-13. PubMed ID: 14627785
[TBL] [Abstract][Full Text] [Related]
7. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
[TBL] [Abstract][Full Text] [Related]
8. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
[TBL] [Abstract][Full Text] [Related]
9. Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence.
Papp KA; Toth D; Rosoph L
BMC Dermatol; 2006 Oct; 6():9. PubMed ID: 17067371
[TBL] [Abstract][Full Text] [Related]
10. Efalizumab in the treatment of psoriasis.
Gupta AK; Cherman AM
J Cutan Med Surg; 2006; 10(2):57-68. PubMed ID: 17241576
[TBL] [Abstract][Full Text] [Related]
11. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.
Joshi A; Bauer R; Kuebler P; White M; Leddy C; Compton P; Garovoy M; Kwon P; Walicke P; Dedrick R
J Clin Pharmacol; 2006 Jan; 46(1):10-20. PubMed ID: 16397279
[TBL] [Abstract][Full Text] [Related]
12. Relapse, rebound, and psoriasis adverse events: an advisory group report.
Carey W; Glazer S; Gottlieb AB; Lebwohl M; Leonardi C; Menter A; Papp K; Rundle AC; Toth D
J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S171-81. PubMed ID: 16488339
[TBL] [Abstract][Full Text] [Related]
13. Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish institute.
Ferrándiz C; Carrascosa JM
Br J Dermatol; 2007 Apr; 156 Suppl 2():24-9. PubMed ID: 17371320
[TBL] [Abstract][Full Text] [Related]
14. Exacerbation of psoriasis under efalizumab therapy.
Rallis E; Verros C; Karanikola E; Valaskatzi A; Papaconstantis M
J Cutan Med Surg; 2009; 13(2):106-9. PubMed ID: 19298780
[TBL] [Abstract][Full Text] [Related]
15. Efalizumab-associated papular psoriasis.
Hassan AS; Simon D; Simon HU; Braathen LR; Yawalkar N
Arch Dermatol; 2007 Jul; 143(7):900-6. PubMed ID: 17638735
[TBL] [Abstract][Full Text] [Related]
16. Efalizumab in the treatment of chronic plaque psoriasis: experiences from the largest psoriasis treatment centre in Denmark.
Kragballe K
Br J Dermatol; 2007 Apr; 156 Suppl 2():7-11. PubMed ID: 17371317
[TBL] [Abstract][Full Text] [Related]
17. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
Gottlieb AB; Gordon KB; Lebwohl MG; Caro I; Walicke PA; Li N; Leonardi CL;
J Drugs Dermatol; 2004; 3(6):614-24. PubMed ID: 15624744
[TBL] [Abstract][Full Text] [Related]
18. Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis.
Papp KA; Ho V; Langley R; Lynde C; Poulin Y; Shear N; Toole J; Zip C
J Cutan Med Surg; 2006; 9 Suppl 1():26-32. PubMed ID: 16633859
[TBL] [Abstract][Full Text] [Related]
19. Efalizumab in moderate-to-severe plaque psoriasis: a retrospective case series analysis from clinical practice.
Cassano N; Mastrandrea V; Buquicchio R; Miracapillo A; Loconsole F; Filotico R; Vena GA
J Biol Regul Homeost Agents; 2008; 22(3):185-93. PubMed ID: 18842172
[TBL] [Abstract][Full Text] [Related]
20. Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial.
Hamilton T; Menter A; Caro I; Compton P; Sobell J; Papp KA
Drug Saf; 2008; 31(8):715-26. PubMed ID: 18636790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
